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Lenalidomide (LEN) treatment leads to red blood cell transfusion independence in 
approximately two-thirds of anemic myelodysplastic syndrome (MDS) patients with del(5q).
(ref. 1) Some patients also experience cytogenetic remissions while in others the del5q 
abnormality persists.(ref. 1) Furthermore, responses also occur in ~25% of MDS patients 
without del(5q).(ref. 2) This suggests that in addition to del(5q) other molecular lesions may 
also be associated with sensitivity to LEN. To date, apart from del(5q), no reliable predictive 
factors for LEN responsiveness have been reported, but clinically patients with early MDS, 
normal/low-risk cytogenetics, or anemia with preserved platelet and neutrophil counts, 
appear to be better LEN candidates than those with more advanced disease, complex 
cytogenetics and cytopenias.(ref. 3) On a molecular level, while initial attempts to 
prospectively identify responders based on gene expression patterns suggested response-
specific signatures,(ref. 4) they have not been translated into an actionable test, and have not 
been validated in non-del(5q) cases.(ref. 5) Recently, the mechanism of action of LEN has 
been attributed to induction of ubiquitination and enhanced degradation of casein kinase 
1A1 (CK1α) by the E3 ubiquitin ligase cereblon.(ref. 6)
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To identify new biomarkers of sensitivity to LEN, using next generation sequencing, we 
determined whether recurrent mutations can help to predict response or resistance to LEN in 
patients with myeloid malignancies.
We have collected a unique cohort of patients with and without del(5) who underwent 
routine therapy with LEN and have adequate clinical and molecular annotation. Informed 
consent in accordance with Institutional Review Board-approved protocols of participating 
institutions was obtained for sample collection from 137 patients (Supplementary Tables 1, 
2), of whom 108 patients were treated with LEN alone (Table 1) and 29 patients received 
LEN in combination with another agent. WHO classification (2008), IPSS-R, and 
International Working Group Criteria (2006) were used to define clinical characters. Patients 
treated at least 2 cycles of LEN were analyzed. Technical details regarding single nucleotide 
polymorphism array have been previously described.(ref. 7) Multi-amplicon deep 
sequencing (TruSeq; Illumina, San Diego, CA, USA) was performed for 45 genes most 
commonly mutated in MDS (Supplementary Table 3). Algorithms for identification of 
somatic lesions, exclusions of germ line alterations, and removal of technical artifacts were 
previously reported.(ref. 8) Logistic regression, Fisher’s exact test and the Mann-Whitney U 
test were used to identify covariates that correlated significantly (two-sided α of 0.05) with 
response. Multivariate logistic regression models were identified using backward stepwise 
selection.
We identified 108 cases of myeloid neoplasms [MDS, MDS/ myeloproliferative neoplasms 
(MPN), or MPN] treated with LEN alone. The median duration of treatment was 5 months 
(range 2–66). Patients were sub-grouped into LEN-responder (n=55) and LEN-refractory 
(n=53) cases (Table 1). Initially, we combined isolated del(5q) (n=29), del(5q) with 
additional cytogenetic abnormalities (n=17), and non del(5q) (n=62) cases. Patient IPSS-R 
risks were grouped as either very low/low/intermediate (92%) or high/very high (8%). 
Hematologic improvement (HI), partial response (PR), complete response (CR, marrow 
CR), or any response (unknown detail) was achieved in 12 (22%), 5 (9%), 19 (34.5%), and 
19 (34.5%) of the cases, respectively. In those treated with LEN alone, the del(5q) group 
overall response rate (ORR) was 65% (30 responded), while in non-del(5q) patients it was 
40% (23 responded) (Supplementary Table 4 & 5). The relatively favorable response rate in 
the non-del(5q) cohort treated in these series may reflect the rational selection of likely 
responders based on empiric criteria, though this ORR was similar to that of previous 
studies.(ref. 1, 2) Analyses of clinical parameters, including age, absolute neutrophil counts, 
blast counts, hemoglobin and IPSS-R scores indicated that responders had significantly 
higher platelets, were more likely to be female, were treated for a longer period of time, had 
lower IPSS-R scores, and were less likely to have excess blasts (Table 1). The resultant 
multivariate model of ORR included as covariates platelets and the presence of isolated 
del(5q); using only the del(5q) cohort the covariates were MDS type and the positivity for 
PRC2 complex lesions. Within isolated low risk MDS cohort, del(5q) remained the only 
predictive covariate (Supplementary Table 6). When stratifying based on del(5q) status, in 
the del(5q) cohort, responders were less likely to have RAEB, and more likely to have lower 
IPSS-R scores, higher platelets, and a longer treatment period (Supplementary Table 4); in 
the non-del(5q) cohort, higher platelets and longer treatment duration also predicted 
response (Supplementary Table 5). When MDS patients were sub-grouped according to the 
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status of disease (low risk: MDS with IPSS-R very low/low/intermediate, MDS/MPN-u, and 
CMML-1 vs. high risk: MDS with IPSS-R (high/very high), all responses occurred in low 
risk category, responders likely to have del (5q), isolated del(5q), 5q-MDS, higher platelets 
and longer treatment duration, while non-responders have normal karyotype and CMML-1 
(Supplementary Table 7 & Figure 1). Within cohorts defined by morphologic features such 
as the presence of ring sideroblasts, uni- vs. multi-lineage dysplasia, the responders were not 
enriched nor a mutational pattern emerged that would predict response (data not shown).
We next examined genomic differences between LEN responders and refractory patients. 
Cytogenetics, namely complex aberrations, -7/del(7q), +8, -20/del(20q), and -Y, were not 
associated with response to LEN but, as expected, del(5q) and isolated del(5q) was 
significantly associated with response: odds ratios (OR) of response in all patients were 2.1 
(1, 4.7) P=.04 and 4.2 (1.5, 13.6) P=.003 for del5q and isolated del5q, respectively (Figure 
1A) and 2.7 (1.2, 6.7) P=.02 and 5.5 (2, 19) P<.001 when focused monotherapy (Figure 1B 
& Supplementary Figure 2). Both del(5q) long (includes the commonly retained region, 
CRR) and short (excludes CRR) showed equal sensitivity to LEN (Figure 1A, 1B).
We also applied targeted sequencing (Supplementary Tables 3) or (in selected cases) whole 
exome sequencing to identify mutations (Supplementary Table 8) that constitute LEN 
resistance factors. Overall, focusing on OR, the number of mutational events per patient was 
not associated with responses (responder vs. non-responder; OR 1.8 vs. 2.3, P=.35). 
Subsequently, we analyzed types of alterations in all cases treated with LEN alone, or with 
combination therapy. U2AF1 (OR < 0.5) was overrepresented in refractory cases, while rates 
for DEAD box RNA helicase combined (DDX41, DDX54, and DHX29), OR = 3.4 (1, 15.1) 
were significantly higher in responders (Figure 1A). Since the total cohort included patients 
with combination therapies, to avoid confounding factors, we focused our analyses on cases 
treated with LEN alone. U2AF1 mutations were significantly associated with failure to 
respond to LEN (0% vs. 11%, P = .01; Figure 1B). When reverse analysis was performed for 
all the genes tested for mutations and deletions, U2AF1 mutations were also less common 
among responders (0% response among U2AF1MT vs. 54% among U2AF1WT cases; OR < 
0.8; Supplementary Figure 2) and 5/6 cases were found in non del(5q) cohort (0% response 
among U2AF1MT vs. 44% among U2AF1WT cases; OR < 1.5; Figure 1C). Previously, MDS 
patients with U2AF1 mutations have been associated with a higher progression rate and poor 
prognosis. (ref. 9) Similarly, TP53 mutations predict response failures suggesting that 
del(5q) MDS with TP53MT might be a clinically important molecular configuration.(ref. 10) 
However, 2 cases with TP53 mutations were found in the context of del(5q) with complex 
karyotype (Figure 1B, C) and both, who received LEN alone, were refractory. In contrast, 
3/4 (75%) TP53 mutant or deletion cases who received LEN+Azacitidine combination 
showed clinical improvement (Figure 1A). When we explored additional LEN sensitivity 
factors in our del(5q) cohort, no individual significant somatic mutations were found (Figure 
1C), though PRC2 complex genes (EZH2, SUZ12, and DNMT3A) were significantly 
associated with poor risk by multivariate analysis, and were consistent with the known 
unfavorable prognosis of EZH2 mutations.(ref. 11) EZH2 and SUZ12 are components of the 
PRC2/EED-EZH2 complex; mutations reduce PRC2 histone methyltransferase activity.(ref. 
12) Previously, CSNK1A1 mutation has been shown to convey a poor prognosis in patients 
with the del(5q) abnormality,(ref. 13) but in our cohort, with a limited number of mutant 
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cases, no impact on response to LEN was noted (OR < 34). Recently, DDX41 mutations 
have been reported to be associated with LEN sensitivity.(ref. 14) Among 7 patients with 
heterozygous DDX41 mutations or deletions who received LEN alone, the response rate was 
57%, OR = 1.3 (0.2, 9.4) (Supplementary Figure 2) and all DDX41 mutants without 
deletions (n=3) were responders (Figure 1B). In the non-del(5q) cohort, DEAD box RNA 
helicase (DDX41, DDX54, and DHX29) mutations/deletions were significantly more 
common in responders (P=.02).
Grouping clone sizes to identify dominant likely ancestral events (SF3B1, TET2, JAK2, 
GPR98, PRPF8, STAG2, DNMT3A, and ZRSR2) did not yield significant results 
(Supplementary Table 9 & Figure 3). In a recent study of patients treated with LEN and 
erythropoietin, combined predictors that do not include mutation status were described, and 
analysis of clonal architecture showed effects on subclonal distribution, whereas loss of 
responsiveness was associated with the re-expansion of the dominant subclone.(ref. 15)
In conclusion, in addition to the presence of del(5q), gender, platelet counts, treatment 
period, MDS type, and IPSS-R, the U2AF1 mutation in the entire cohort, mutations in TP53 
in the del(5q) cohort, and DEAD box RNA helicases in the non-del(5q) cohort grouped with 
responses to LEN.
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Figure 1. 
Correlations of gene mutation/deletion and cytogenetics abnormality with Lenalidomide 
response. (A) Response rate to LEN alone and LEN combination therapy in patients with 
gene mutations/deletions or cytogenetic abnormalities compared with wild type cases. (B) 
Spectrum of mutations and deletions in myeloid malignancy between responder (n=55) and 
non-responder (n=53) to Lenalidomide (LEN) monotherpay, * mutation or cytogenetic 
abnormality; p<.05. Red, blue, yellow, gray and white indicate mutations, deletions, 
cytogenetic abnormalities, wild type and no data respectively. Triangle indicated mutation
+deletion of the corresponding genes affected by hypomorhic/loss of function mutations. (C) 
Response rate to LEN monotherapy in del(5q) and non-del(5q) patients with gene mutations/
deletions or cytogenetic abnormalities compared with wild type cases; * <.05. del(5q) short: 
excluding commonly retained regions (CRR; q11.1-q14.2 and/or q34-qter), del(5q) long: 
including CRR. Inf: infinity.
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Table 1
Clinical Characteristics of patients of Myeloid malignancy treated with LEN monotherapy
Responder Non-responder P
Sample size for sequencing 55 53
Diagnosis
MDS (n=91) 48 43 .2
Low risk (RA, RARS, RCMD, 5q-MDS) 42 29
.009*
RA (FAB criteria) 8 5 .55
RARS 6 7 .78
RCMD 9 14 .24
5q-MDS 19 3 <.001*
High risk (RAEB-1) 2 11
.008*
MDS/MPN (n=10) 3 7 .2
CMML-1 0 4 .06
MDS/MPN unclassifiable 3 3 1
MPN (n=7) 4 3 1
Myelofibrosis 4 3 1
Demographics
Age (n=40 vs. n=46)
Median (range) 69 (20–90) years 72 (30–85) years .95
Gender (n=41 vs. n=46)
Female 25 17
.03*
IPSS-R (n=48 vs. n=42)
High risk (very high, high) 0 7
.008*
Low risk (intermediate, low, very low) 48 35
.008*
Blood counts before treatment (n=36 vs. n=38)
Hemoglobin level, median (quartile 1–3) 8.6 (8–9.6) g/dl 8.9 (8.0–10.1) g/dl .56
Neutrophil count, median (quartile 1–3) 1.8 (1.1–3.0) ×109/l 1.8 (1.2–4.0) ×109/l .39
Platelet count, median (quartile 1–3) 284 (140–366) ×109/l 85 (33–196) ×109/l <.001*
Bone marrow (n=34 vs. n=37)
Blast >5% 2 6 .15
Cyotogenetics (n=53 vs. n=50)
Normal 18 26 .07
Any abnormal cytogenetics 35 24 .07
Del(5q) with or without other mutations 30 16
.02*
Isolated del(5q) 23 6 <.001*
Del(5q) short 13 8 .2
Del(5q) long 12 7 .2
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Responder Non-responder P
Complex 3 7 .19
-7/del(7q) with or without other mutations 2 2 1
Trisomy 8 with or without other mutations 4 3 1
-20/del(20q) with or without other mutations 2 2 1
-Y with or without other mutations 4 1 .36
Other 4 13 N/A
Treatment period (n=30 vs. n=36)
Median (range) 12.5 (2–66) months 3.5 (2–19) months <.001*
Response
Complete response (CR/ marrow CR) 12 N/A N/A
Partial response (PR) 5 N/A N/A
Hematologic improvement (HI) 19 N/A N/A
Unknown detail 19 N/A N/A
IPSS-R: Revised International Prognostic Scoring System, LEN: Lenalidomide, Aza: Azacytidine
MDS: Myelodysplastic syndrome, MPN: Myeloproloferative neoplasms, RA: Refractory anemia
RCUD: Refractory cytopenias with unilineage dysplasia, RARS: Refractory anemia with ring sideroblasts
RCMD: Refractory cytopenia with multilineage dysplasia, RAEB: Refractory anemia with excess blasts
CMML: Chronic myelomonocytic leukemia, MDS type is unknowen in 7 cases.
del(5q) short: excluding commonly retained regions (CRR; q11.1-q14.2 and/or q34-qter),
del(5q) long: including CRR, N/A; Not applicable,
*P<.05
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